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Abstract
Neurexins (NRXNs) are synaptic cell adhesion molecules having essential roles in the assembly and
maturation of synapses into fully functional units. Immunocytochemical and electrophysiological
studies have shown that specific binding, across the synaptic cleft, of the ectodomains of presynaptic
NRXNs and postsynaptic Neuroligins (NLGNs) have the potential to bidirectionally coordinate and
trigger synapse formation. Moreover, in vivo studies as well as genome-wide association studies pointed
out implication of NRXNs in the pathogenesis of cognitive disorders including autism spectrum
disorders (ASDs) and different types of addictions including opioid and alcohol dependences,
suggesting an important role in synaptic function. Despite extensive investigations, the mechanisms by
which NRXNs modulate the properties of synapses remain largely unknown. We report here that α- and
γ-secretases can sequentially process neurexin-3β(NRXN3β), leading to the formation of two final
products: a ~80 kDa N-terminal extracellular domain of Neurexin-3β (sNRXN3β) and ~12 kDa
C-terminal intracellular NRXN3β domain (NRXN3β-ICD), with both of them being potentially
implicated in the regulation of NRXNs and NLGNs functions at the synapses, or in yet unidentified
signal transduction pathways. We further report that this processing is altered by several PS1 mutations
in the catalytic subunit of the γ-secretase that causes early-onset familial Alzheimer's disease.
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Neurexins (NRXNs) are synaptic cell adhesion 
molecules having essential roles in the 
assembly and maturation of synapses into 
fully functional units.  Immunocytochemical 
and electrophysiological studies have shown 
that specific binding, across the synaptic cleft, 
of the ectodomains of presynaptic NRXNs and 
postsynaptic Neuroligins (NLGNs) have the 
potential to bidirectionally coordinate and 
trigger synapse formation. Moreover, in vivo 
studies as well as genome-wide association 
studies pointed out implication of NRXNs in 
the pathogenesis of cognitive disorders 
including autism spectrum disorders (ASDs) 
and different types of addictions including 
opioid and alcohol dependences, suggesting an 
important role in synaptic function. Despite 
extensive investigations, the mechanisms by 
which NRXNs modulate the properties of 
synapses remain largely unknown. We report 
here that α- and γ-secretases can sequentially 
process neurexin-3β  (NRXN3β), leading to 
the formation of two final products: a ~80 
kDa N-terminal extracellular domain of 
Neurexin-3β  (sNRXN3β) and ~12 kDa C-
terminal intracellular NRXN3β  domain 
(NRXN3β-ICD), with both of them being 
potentially implicated in the regulation of 
NRXNs and NLGNs functions at the synapses, 
or in yet unidentified signal transduction 
pathways. We further report that this 
processing is altered by several PS1 mutations 
in the catalytic subunit of the γ-secretase that 
cause early-onset familial Alzheimer’s disease.  
Neurexins (NRXNs) are type I 
transmembrane neuronal adhesion receptors that 
exit and function predominantly at presynaptic 
terminals. In mammals, NRXNs are encoded by 
three genes NRXN1, NRXN2, and NRXN3. 
From each single gene, and by virtue of two 
independent promoters, two NRXN isoforms are 
synthetized: the longer α-NRXNs and the shorter 
β-NRXNs (essentially N-terminally truncated α-
NRXNs). Moreover, each of the 6 transcripts 
undergoes extensive alternative splicing, 
potentially giving rise to thousands of different 
Neurexin isoforms (1-3). At the protein level, 
NRXNs have several known extracellular 
ligands: neurexophilins, dystroglycans, 
neuroligins (NLGNs) (reviewed in (4)), the 
recently identified LRRTM2 (5,6), the complex 
Cbln1/GluRδ2 (7) and GABAA receptors (8). 
Insights into the role of NRXNs/NLGNs 
complexes for synapse development came from a 
study from Scheiffele et al (9). In the latter, the 
development of an artificial synapse assay 
involving co-culture of non-neuronal and 
neuronal cells demonstrated that 
NRXNs/NLGNs interaction is sufficient to 
trigger postsynaptic and presynaptic 
differentiation. In this context, ligated neurexins 
not only signal to recruit on the presynaptic side 
neurotransmitter vesicles associated with the 
exocytotic machinery, but also instruct 
postsynaptically the recruitment of NMDA or 
GABA receptors and scaffolding proteins PSD-
95 and Gephyrin (10,11). Taken together, 
NRXNs and NLGNs appear to interact and 
signal bi-directionally between pre- and 
postsynaptic sites to assemble some of the 
elements required for fully functional synapses.  
 Based on the findings that particular variants 
of NRXNs preferentially bind to NLGN1 or 
NLGN2 and that NLGN1 and NLGN2 are 
differentially localized to excitatory or inhibitory 
synapses (12,13) a concept emerged where 
differential assembly of specific postsynaptic 
elements, dictated by NRXNs and their physical 
interaction with NLGNs is regulating the balance 
between excitatory and inhibitory synapses (E/I 
ratio) (12). Consequently, any alteration of this 
process might have important implications in 
synaptic activity and plasticity. Alterations in 
this process might also have important 
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 2 
implications on neurodevelopmental psychiatric 
disorders such as autism, which is thought to 
result from an imbalanced E/I ratio (reviewed in 
(14)).  
Strong evidence also exists supporting 
essential roles for the α-secretase 
TACE/ADAM17, β-secretase BACE1, and γ-
secretase in regulating synaptic functions.  
The α-secretase TACE/ADAM17 (or tumor 
necrosis factor-α converting enzyme) is a 
metalloprotease that was primarily identified by 
its ability to cleave the pro-inflammatory 
cytokine TNFα (15,16). TACE/ADAM17 
proteolytic activity releases by “ectodomain 
shedding” functional domains from a growing 
list of membrane anchored substrates including 
the Notch receptor, the epidermal growth factor 
receptor (EGFR), the amyloid precursor protein 
(APP), and other cytokine receptors and 
adhesion receptors (reviewed in (17)). At the 
synaptic level, adhesion receptors such as L1, 
NCAM or SynCAM1 but also the neuronal 
pentraxin receptor (NPR) were identified as 
TACE/ADAM17 substrates (18-22). While 
TACE-dependent processing of L1 and NCAM 
was shown to be involved in neurite outgrowth, 
the analysis of mechanisms regulating NPR 
cleavage revealed the role of TACE/ADAM17 in 
synaptic plasticity. TACE is indeed required for 
cleaved NPR to act in hippocampal and 
cerebellar synapses by promoting AMPAR 
endocytosis, a process that is essential for 
durable long-term depression (18).  
The β-secretase BACE1 is a membrane 
tethered aspartyl protease that cleaves the 
amyloid-β precursor protein (APP) to generate 
APP-C99, a 99 amino-acid long C-terminal 
domain of APP, which, following processing by 
γ-secretase, leads to the formation of the 
pathogenic β-amyloid peptides (Aβ) implicated 
in Alzheimer’s disease (23). However, 
characterization of BACE1 substrates other than 
APP (including the voltage-gated sodium 
channel Na(v)1 beta2-subunit and neuregulin 1), 
pointed out the role of BACE1 in neuronal 
functions (24,25). Studies analyzing BACE1 
knock-out mice indeed highlighted dysfunctions 
in synaptic transmission and plasticity (26-28). 
In addition, BACE1 seems to be essential for 
cognitive and emotional functions since BACE1 
transgenic null mice or mice overexpressing 
BACE1 displayed behavioural changes 
(26,29,30). 
γ-Secretase is an intra-membrane cleaving 
multisubunit protease complex made of at least 
four different proteins: presenilin1 or 2 (PS1 or 
PS2), NCT, APH-1, and PEN-2 (23). Mutations 
in PS1, the catalytic subunit of the protease, are 
the most common cause of early-onset familial 
Alzheimer’s disease (FAD), causing synaptic 
dysfunction leading to memory loss and 
neurodegeneration. Indeed, behavioral tests as 
well as electrophysiolgical studies on conditional 
knock-out PS1 and PS2 null mice, revealed 
impairments in hippocampal memory and age-
dependent neurodegeneration due to neuronal 
loss (31). Interestingly, and based on a study 
focusing on PS1 cDKO mice, Zhang. et al. (32) 
assigned a specific presynaptic function to 
PS1/ γ-secretase. They further demonstrated that 
loss of PS1 impairs the activity-dependent 
regulation of neurotransmitter release in mature 
neurons (32). Collectively, these findings 
suggest a substantial role of PS1/ γ-secretase in 
synaptic plasticity and neuronal survival. 
Considering the essential roles of the 
presynaptic NRXNβ, TACE/ADAM17, BACE1 
and γ-secretase in both neurotransmitter release 
and synaptic plasticity, we investigated whether 
NRXN3β, the most widely expressed variant of 
β-neurexin (33), and γ-secretase are functionally 
associated, and assessed whether NRXN3β can 
be processed by α-, β-, and γ-secretases.  
 
 
Experimental Procedures 
 
Expression vectors- human NRXN3β 
(KIAAO743) cDNA lacking any insert at splice 
site 4, was purchased from Openbiosystems, 
sequenced and subcloned (with a Flag tag at the 
N-terminus) into the mammalian expression 
vector pCDNA 3/Neo (+) (Invitrogen), or pSIN 
lentiviral transfer vector (34). The sequences 
encoding for the NRXN3β-CTFs were subcloned 
into the pet21b (+) (Novagen) expression vector 
with a Flag tag at the C-terminus. The PS1 WT, 
PS1 L166P, PS1 P436Q and the PS1 ΔΕ9 
constructs were subcloned into the lentiviral 
transfer vector pSIN. For generation of 
NRXN3β-FL-Gal4-VP16 (NRXN3β-FL-GV), 
the Gal4 DNA binding domain and the 
transactivation domain of the herpes simplex 
virus protein VP-16 were fused to the C-terminal 
end of the human NRXN3β. The NRXN3β-GV 
encoding sequence was then inserted into the 
pcDNA TM 5/TO vector (Invitrogen) and its 
expression placed under the control of two 
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 3 
tetracycline operator sequences (TO). The APP-
C99-GV construct was a gift from M. Wolfe 
(35). The luciferase reporter vector pLG4.31 
(Promega) contains the synthetic firefly 
luciferase gene (luc 2) placed under the control 
of the GAL4UAS response element. 
 
Cell lines and cultures- Chinese hamster ovary 
(CHO) cell lines, human embryonic kidney cells 
(HEK 293T), WT and DKO PS1/PS2 Mouse 
Embryonic Fibroblasts (MEFs) were routinely 
grown in DMEM with 10% foetal bovine serum 
(FBS) and penicillin/streptomycin in a 
humidified 5% CO2 atmosphere. The CHO cell 
line expressing stably Flag-tagged NRXN3β was 
maintained in DMEM 10% FBS supplemented 
with 300 µg/ml of Geneticin G418 (Gibco). T-
Rex Hela cells stably expressing the repressor of 
tetracyclin (Invitrogen) were maintained in E-
MEM medium with 10% FBS, 2mM L-
Glutamine, 1% P/S and 5µg/ml of blasticidin. 
Mouse primary cortical neurons (PCN) were 
prepared from embryonic day 17 Of1 mouse 
foetal brains. Cortices were dissociated by 
repeated passages through a fire-polished Pasteur 
pipette. The dissociated cells were plated in 
DMEM + 10% FBS on poly-D-lysine coated 
plates at 1x105 cells/cm2. After 4 - 6 hrs, the 
medium was changed and the cells maintained in 
neurobasal medium (Gibco) supplemented with 
B27 (Invitrogen) and 2 mM L-Glutamine at 
37°C in a humidified 5% CO2 atmosphere. The 
cells were treated with 10µM cytosine 
arabinoside after 4 days in vitro (DIV). PCN 
treatments with 10 µM of N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester (DAPT, Sigma), 10 µM Compound E 
(Alexis), 0.5 µM Phorbol 12-myristate 13-
acetate (PMA, Sigma), 20 µM TAPI-1 
(Calbiochem), 5 µM GL189 (Calbiochem) were 
carried out for 16 hours, at DIV13. PCN 
treatments with either 50mM of KCl or 50µM of 
L-Glutamate were carried out at DIV 13. Briefly, 
fresh neurobasal medium (Gibco), supplemented 
with either L-Glutamate or KCl or an equal 
volume of PBS, was added to cells and cells 
were incubated 15 minutes at 37°C in a 
humidified 5% CO2 atmosphere. Neurons were 
then washed with PBS and microsomal 
membranes prepared as described below.  
The CHO cells expressing stably NRXN3β 
were washed with ice-cold phosphate-buffered 
saline (PBS) and lysed in 1% NP40 HEPES 
buffer (50 mM Hepes, 150 mM NaCl, 5 mM 
MgCl2, 5 mMCaCl2, 1% Nonidet P-40 and a 
cocktail of protease inhibitor (Roche 
Diagnostics)). Protein concentrations were 
determined by using the BCA protein assay kit 
(Pierce) and whole cell protein extracts were 
separated on 4-12 % Bis-Tris gels (Invitrogen) 
and transferred onto nitrocellulose membranes to 
detect Flag-tagged NRXN3β (M2 anti Flag, 
Sigma) as described below. For the PCN, 
membrane fractions were prepared by osmotic 
shock. After two washes with PBS and two 
washes with a hypotonic buffer (50 mM 
HEPES), cells were passed through a 25-Gauge 
syringe and the homogenates were centrifuged at 
3’000g for 10min at 4°C. The supernatants were 
collected and centrifuged at 100’000g for 1hr at 
4°C and the pellets resuspended in 1% NP-40 
HEPES. Solubilized cellular membranes were 
separated on 4-12 % Bis-Tris gels (Invitrogen) 
and transferred onto PVDF membranes to detect 
endogenous NRXNs as described below. 
Ectodomain shedding assays- 16 hours after 
transfection of HEK 293T cells with FL-
NRXN3β, DMEM 10% FBS medium was 
replaced with fresh serum free DMEM medium 
containing TAPI-1 (20µM) or PMA (0.5µM). 
Following 24 hours incubation, the media were 
collected, centrifuged at 1000g for 3min, and 
1ml of each supernatant was collected for TCA 
precipitations.  
Protein expression and purification- For the 
purification of cellular NRXN3β−CTF 
substrates, 10 x 10 cm dishes of HEK 293T cells 
transiently transfected with FL-NRXN3β-Flag 
were incubated for 16 hours with 10µM DAPT 
and lysed in ice-cold 1% CHAPSO-HEPES lysis 
buffer (50 mM Hepes, 150 mM NaCl, 5 mM 
MgCl2, 5 mMCaCl2, 1% CHAPSO, protease 
inhibitor cocktail). The lysate was centrifuged at 
14’000 rpm for 1hr at 4°C and the supernatant 
incubated overnight with the M2 anti-Flag 
affinity resin. Following 2 washes in 1% 
CHAPSO-HEPES and one wash in 0.2% 
CHAPSO-HEPES, the bound proteins were 
eluted in 100 µl 0.2% CHAPSO-HEPES 
containing 0.2 mg/ml Flag peptides, pooled, and 
used for the in vitro γ-secretase assays. For the 
expression and purification of recombinant 
NRXN3β-CTF substrates, E. coli strain BL21 
(DE3) (Invitrogen) was transfected with 
pet21b(+) (Novagen) expressing the Flag-tagged 
NRXN3β-CTFs. The expression of the proteins 
was induced for 4 hours at 37°C, in 1L of LB/ 
ampicillin containing 1 mM IPTG. Following 
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extraction of inclusion bodies (as described in 
(36)) the NRXN3β-CTFs were refolded by 
dialysis in 10 mM Tris pH 7.0, 150 mM NaCl, 
1% Triton X-100, and purified using the M2 
anti-Flag affinity resin. Finally, the Flag-tagged 
NRXN3β-CTFs were eluted in 5x1 mL fractions 
in 1% Nonidet P-40 (NP-40), 100 mM glycine 
pH 2.7. The purity of the CTFs was confirmed 
by SDS-PAGE using Coomassie staining. 
 
Cell-free γ-secretase activity assays- In vitro 
γ-secretase activity assays with purified γ-
secretase were performed as previously 
described (37). Briefly, the reactions contained 
recombinant APP-C99 or NRXN3β-CTF 
(substrates expressed in E. coli as a fusion 
protein consisting of a Met for translation 
initiation, and the Flag tag sequence, each at 1 
µM), purified γ-secretase or from solubilized 
membrane fractions, 0.025% 
phosphatidylethanolamine (PE) and 0.10% 
phosphatidylcholine (PC). All the reactions were 
stopped by adding Laemmli sample buffer, and 
the samples were assayed by Western blot for 
ICD-Flag as described below. 
γ-secretase activity assays with isolated 
membranes were performed as described in (38). 
Briefly, CHO cells stably overexpressing 
NRXN3β were collected in a hypotonic buffer 
(10 mM MOPS pH7.0, 10 mM KCl, protease 
inhibitors cocktail (Roche Diagnostics)) and 
homogenized on ice by 10 passages through a 
25-Gauge needle. The homogenates were 
centrifuged at low speed (1’000g, 15min, 4°C) 
and the postnuclear supernatants further 
centrifuged at 16’000g for 40 min at 4°C to 
pellet the membranes. These were resuspended 
in the assay buffer (150 mM Na Citrate pH 6.4, 
protease inhibitor cocktail) and incubated for 3 
hrs at 37°C with a gentle shaking (300 rpm) in 
the presence or absence of 1 µM DAPT or 1 µM 
Compound E. Alternatively, isolated membranes 
were prepared from cells incubated for 16 hours 
in the presence or absence of 10 µM DAPT, and 
incubated for 2 hrs at 37°C. Membrane 
preparations from KCl or L-Glutamate 
stimulated PCN were incubated for 4 hours in 
assay buffer (150 mM Na Citrate pH 6.4, 
protease inhibitor cocktail) at 37°C. Next, 
membrane protein extracts were prepared by 
incubating the membranes in RIPA buffer 
(25mM Tris pH 7.6, 150mM NaCl, 1% NP-40, 
1% sodium deoxycholate, 0.1% SDS) for 1 hour 
on ice before adding Laemmli buffer and western 
blotting. 
 
Transactivation assays- T-Rex Hela cells were 
grown in 24 well plates (2.5–5x105 cells/well) 
and each well was cotransfected with NRXN3β-
FL-GV encoding plasmid and the firefly 
luciferase reporter plasmid. Transfected cells 
were incubated for 24 hours with 1µg/ml of 
tetracycline in the presence or absence of 10 µM 
DAPT. Addition of tetracycline relieves 
transcriptional repression from the tetracycline 
operator and therefore allows expression of FL-
NRXN3β-GV or APP-C99-GV. Cells were then 
harvested and used for luciferase activity assays. 
Briefly, cells were lysed for 5 min in 100 µl Glo 
lysis buffer, and the luciferase activity was 
measured by mixing 90 µl of each lysate and 
Bright-Glo luciferase assay reagent (Promega) in 
96-well Nunc MaxiSorp plates (Nunc, Roskilde, 
Denmark). Following 5 min incubation at room 
temperature, the luminescence emitted in 
individual wells was monitored by using an 
automated plate reader (Tecan Infinite F500; 
Tecan, Grödig, Austria).  
 
Western blotting and antibodies- For Western 
blot analysis of FL-NRXN3β, PS1-NTF, APP, 
and β-actin the samples were run on 4-12% Bis-
Tris PAGE gels, transferred onto nitrocellulose 
membranes and probed with the rabbit 
polyclonal anti-Neurexin (Synaptic systems) or 
M2 anti-Flag (Sigma) (for FL-NRXN3β), anti-
PS1 (1563, Millipore), and anti-amyloid 
precursor protein (APP) c-terminal antibody 
(Sigma). A rabbit antiserum was raised against 
an N-terminally NRXN3β specific sequence 
(Eurogentec). NRXN3β-GV and APP-C99-GV 
were detected by using an anti VP16 antibody 
(Abcam, UK).  
 
Lentiviruses production- The production of 
lentiviral particules was performed by transient 
transfection of HEK 293T cells (CalPhosTM 
Mammalian Transfection Kit, Clontech) with the 
vectors pSIN containing the gene of interest 
(pSIN-NRXN3β-Flag, pSIN-PS1 WT, pSIN-
PS1-L166P, pSIN-PS1-P436Q, or pSIN-PS1-
ΔΕ9) together with the packaging system and a 
plasmid encoding for the virion envelope 
(pMD2G), as previously described in (34). 18 
hours after transfection HEK 293T cells were 
washed and fresh medium added. During the 
following 48 hours, conditioned media were 
harvested twice and kept at 4°C. Media were 
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 5 
then filtered, ultracentrifuged for 2 hours at 16°C 
and 19’500 rpm, and the lentiviral pellet 
resuspended in PBS to concentrate by 1000x the 
particles. 2*106 of each CHO-NRXN3β stable 
cells or MEF cells expressing transiently 
NRXN3β were infected with 2µl or 4µl of 
lentiviral preparations. After 36 hours of 
incubation, infected cells were lysed with 
HEPES NP-40 buffer and total protein extracts 
were immunoblotted as described above.  
 
Quantifications- The quantifications of 
NRXN3β- or APP-CTFs (Figs. 1E and 3A) as 
well as the AICDs and NRXN3β-ICDs (Figs. 5B 
and 5C), were performed using ImageJ and the 
previously described densitometric method 
(http://lukemiller.org/journal/2007/08/quantifyin
g-western-blots-without.html). The relative 
CTFs levels in Fig. 1E were expressed as % of 
DMSO control. In Fig. 3A, the experimental 
hNRXN3β- and APP-CTFs values were 
normalized to the full-length hNRXN3β- and 
APP, respectively. In Figs. 5B and 5C, ICD 
levels were expressed as % of (+ γ-secretase) 
control. 
 
Animals. We carried out all animal 
experiments in accordance with the local and 
federal directive for care and use of laboratory 
animals.  
 
RESULTS 
  
NRXN3β is sequentially cleaved by α- and γ-
secretases. Several requirements specifying γ-
secretase substrates are shared by almost all 
substrates. First, the substrates are type I 
transmembrane proteins, with the N-terminal 
ectodomains facing the extracellular side. Next, 
they undergo an initial shedding by α- and/or β-
secretases, thus leading to the formation of an 
extracellular soluble protein as well as a C-
terminal membrane-embedded fragment (CTF). 
Finally, the CTFs are further processed by γ-
secretase into intra-cellular domains (ICD) (for 
reviews, see (39,40)). Based on these 
requirements, and in order to assess whether 
NRXN3β can be processed by α-, β-, and γ-
secretases, intracellular accumulation of neurexin 
CTFs in response to ectodomain shedding by α- 
and/or β-secretase activities, in conjunction with 
γ-secretase inhibition (a common characteristic 
among known γ-secretase substrates) was probed 
in HEK293T cells transiently expressing human 
NRXN3β (Fig. 1A), in CHO cells stably 
expressing NRXN3β (Fig. 1B), as well as in 
untransfected mouse primary cortical neurons 
(PCN) at DIV 14 (Fig. 1C). Flag-tagged 
NRXN3β-CTFs were detected with an anti-flag 
antibody (Figs. 1A,B) while an antibody 
targeting the C-terminal part of Neurexins was 
used to detect endogenous NRXN-CTFs (Fig. 
1C). As shown in Fig. 1, treatments with γ-
secretase specific inhibitors N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester (DAPT) and compound E (CpdE) 
triggered the accumulation of a major ~16-kDa 
Flag-tagged NRXN3β-CTF in HEK293T and 
CHO cells (Figs. 1A,B), and a major ~15-kDa 
endogenous NRXN-CTF in PCNs (Fig. 1C), 
migrating at the size of NRXN3β-CTF purified 
from CHO cells (Fig. 1C, lane 1). Because of the 
high homology existing amongst the different 
isoforms of Neurexin CTFs (Fig. 1D), and since 
the anti-NRXN antibody used in this experiment 
has been generated with a mixture of 
recombinant cytoplasmic tails of rat NRXNs 1, 2 
and 3, it is likely that the latter also targets in 
PCNs Neurexin CTFs derived from other NRXN 
isoforms. Next, DAPT and CpdE, in 
combination with Phorbol 12-myristate 13-
acetate (PMA, a PKC activator stimulating α-
secretases), further elevated the cellular levels of 
NRXN3β-CTFs (Fig. 1A, lane 4; Fig. 1B, lanes 
5 & 6; Fig. 1C, lanes 5 & 6). As shown in Figs. 
1A (lanes 3 & 4) and 1B (lanes 5 & 6), PMA 
stimulation of HEK293T and CHO cells was 
associated with increased levels of NRXN3β-FL. 
Since PMA alone does not affect the levels of 
NRXN3β-CTFs (compare lane 3 with lane 1 in 
Fig. 1A), changes observed at the levels of these 
CTFs in cells incubated with DAPT or CpdE in 
combination with PMA should be attributed to 
the inhibition of γ-secretase. To further confirm 
that the shedding of NRXN3β is α-secretase 
specific, cells were treated with TAPI-1, a 
metalloprotease inhibitor with some specificity 
for TACE, in combination with DAPT and 
CpdE. In sharp contrast to the BACE inhibitors 
GL189 (Fig. 1) and C3 (not shown), TAPI-1 
strongly reduced the DAPT/CpdE-induced 
accumulation of NRXN3β-CTFs (Fig. 1A, 
compare lanes 6 & 2; Fig. 1B, compare lanes 7 
& 3, lanes 8 & 4, lanes 9 & 3, and lanes 10 & 4; 
Fig. 1C, compare lanes 6 & 2, lanes 7 & 3, lanes 
8 & 4, and lanes 9 & 3). Together, these data 
indicate that a protease of the α-secretase family, 
most likely TACE/ADAM17, is involved in full-
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length NRXN3β (FL-NRXN3β) cleavage. 
Furthermore, co-treatment of cells with γ-
secretase inhibitors DAPT/CpdE and α-secretase 
inhbitor TAPI-1 suggest, when compared to cells 
treated with DAPT or TAPI-1 only, that 
NRXN3β cleavage by α-secretase occurs prior to 
γ-secretase NRXN3β-CTF processing.  
To put our data into the physiological context 
of the synapse, we next assessed whether 
cleavage of endogenous neuronal neurexin by α- 
and γ-secretases can be modulated by neuronal 
activity. Treatment of primary neuronal cultures 
with KCl, resulting in membrane depolarization 
and neurotransmitter release at synaptic endings, 
has previously been shown to stimulate, via 
activation of glutamate receptors, γ-secretase 
cleavage of N-Cadherin (38). We therefore 
examined the effects of 50mM KCl or 50 µM L-
Glutamate mediated stimulation of PCN on 
NRXN processing. After 15 min of stimulation, 
membranes were prepared from the PCN and 
used in in vitro activity assays in the presence or 
absence of 1µM of DAPT. As shown in Fig. 1E, 
endogenous NRXN-CTF levels were elevated by 
~1.7-fold when cells had been previously treated 
with L-Glutamate (Fig. 1E, lanes 3 & 4) or KCl 
(Fig. 1E, lanes 5 & 6), when compared to 
NRXN-CTFs in non-treated cells (Fig.1E, lanes 
1 & 2). Intracellular accumulation of CTFs in 
response to the combined effect of N-terminal 
shedding and γ-secretase inhibition is a common 
feature of known γ-secretase substrates. 
Therefore, and consistent with both α-secretase  
activation and γ-secretase inhibition hypotheses, 
the accumulation of NRXN-CTFs in cells can be 
attributed to α-secretase activation, γ-secretase 
inhibition, or a combination of both. Yet, DAPT 
increases the levels of NRXN-CTF levels in L-
Glutamate/ KCl stimulated neurons, further 
supporting enhanced α-secretase activity and 
excluding the possibility that the observed 
increase in NRXN-CTFs after stimulation is 
solely due to reduced γ-secretase activity (Fig 
1E, compare lane 2 to lanes 4 and 6). Together, 
these results suggest that NRXN processing by 
α- and γ-secretases is subjected to a regulation 
by synaptic activity.  
 
NRXN3β ectodomain shedding and 
extracellular sNRXN3β production. To assess 
whether full-length NRXN3β undergoes 
ectodomain shedding, serum-free media of 
HEK293T cells transiently expressing 
NRXN3β were collected, total proteins TCA 
precipitated, and probed for soluble NRXN3β  
(sNRXN3β) with an N-terminal specific 
NRXN3β antibody (Fig. 2A). As a control, the 
same samples were further analyzed by western 
blotting using an antibody targeting the C-
terminally Flag-tagged full-length NRXN3β 
(Fig. 2B). We found a prominent ~80 kDa band 
consistent with the expected position of 
sNRXN3β to be detected by the N-terminal (Fig. 
2A), but not C-terminal (Fig. 2B) specific 
NRXN3β antibodies. These data demonstrate 
that a C-terminal truncated NRXN3β species, but 
not the full length protein, is detected in the 
conditioned media of HEK293T cells expressing 
transiently NRXN3β. Further supporting the 
NRXN3β ectodomain shedding by α-secretase, 
elevated levels of sNRXN3β were observed in 
cells incubated for 16 hours with PMA (Fig. 2A, 
compare lane 4 with lane 3) while reduced levels 
of sNRXN3β were found in cells incubated for 
16 hours with TAPI-1 (Fig. 2A, compare lane 5 
with lane 3).  However, the substantial amount of 
sNRXN3β remaining in the conditioned medium 
after TAPI-1 treatment (Fig. 2A, lane 5) 
indicates either incomplete action of the inhibitor 
or the contribution of other α-secretase-like 
proteases responsible for cleaving NRXN3β. 
Fully consistent with α-secretase cleavage, 
changes seen in the levels of extracellular 
NRXN3β ectodomains released after shedding 
mirrored changes seen in intracellular CTF levels 
(Figs. 1&2).  
 
 
Alzheimer’s disease-causing Presenilin 
mutations impair NRXN3β  processing. To 
further support the γ-secretase-mediated cleavage 
of NRXN3β, we assessed the impact on 
NRXN3β processing of PS1-L166P, PS1-P436Q 
and PS1-ΔΕ9, mutations/deletion in the catalytic 
core of γ-secretase causing early-onset forms of 
Alzheimer’s disease. To do so, CHO-cells stably 
expressing NRXN3β were transduced with 
increasing amounts (to highlight the dose-
dependent effect) of PS1 WT or the mutants 
PS1-L166P, PS1-P436Q, and PS1-ΔE9 (Fig. 
3A). For accurate quantification of both 
NRXN3β-CTF and APP-CTF, and since 
overexpression of PS1 (especially PS1-L166P 
and PS1-P436Q) apparently affects the levels of 
full-length NRXN3β (Fig. 3A, top panel), the 
levels of CTFs were normalized to these of full-
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 7 
length NRXN3β and APP (Fig. 3A, bottom 
panel). First, overexpression of PS1 WT did not 
affect NRXN3β-CTF and APP-CTF levels when 
compared to that of non-transduced cells (Fig. 
3A, compare lanes 2 and 3 with lane 1 – 
quantifications in bottom panel). Next, and while 
PS1-ΔΕ9 mutant only slightly increased 
NRXN3β and APP-CTF levels, overexpression 
of either PS1-L166P or PS1-P436Q dramatically 
increased NRXN3β-CTFs and APP-CTF levels 
in a dose-dependent manner (Fig. 3A, lanes 4-9 – 
quantifications in bottom panel). These results 
suggest that the partial loss of function 
Alzheimer’s disease causing mutations PS1-
L166P and PS1-P436Q impair NRXN3β 
processing and lead to the intracellular 
accumulation of NRXN3β-CTFs. 
 
Loss of γ-secretase activity impairs NRXN3β 
processing. We further investigated the levels of 
NRXN3β-CTFs in PS1/PS2 double knock-out 
mouse embryonic fibroblasts (MEFs PS1/PS2 
DKO, lacking functional presenilins-1 and-2 
(41,42)) transduced with NRXN3β lentiviruses 
(Fig. 3B). When compared to wt MEFs, elevated 
NRXN3β-CTF levels were found in the MEFs 
PS1/PS2 DKO (Fig. 3B, compare lane 2 with 
lane 1). To demonstrate that this failure to 
process NRXN3β-CTFs was a consequence of 
PS loss, human PS1 WT was reintroduced in the 
MEFs PS1/PS2 DKO by lentiviral transduction. 
To confirm the rescued γ-secretase activity in 
these cells, both expression and activity levels of 
human PS1 were assessed by western blot using 
a PS1 N-terminal specific antibody (to follow 
PS1-NTF, the matured and active form of PS1), 
and an anti-APP-CTF antibody (to follow the 
levels of APP-CTFs). Reduced APP-CTF levels 
in PS1-expressing MEFs PS1/PS2 DKO (when 
compared to that of non-transduced cells) 
confirmed the rescued γ-secretase activity (Fig. 
3B, compare lane 3 with lane 2). Further 
supporting an essential role of PS1 in the 
processing of NRXN3β, the accumulation of 
NRXN3β-CTFs observed in MEFs PS1/PS2 
DKO cells was reversed in the rescued cells. 
 
NRXN3β processing in a cell-based 
luciferase reporter assay. In order to further 
assess Neurexin processing at the cellular level, 
we developed a cell-based reporter gene assay 
specific for NRXN3β (described in Fig. 4A), 
similar to that specific for APP-C99 (35). T-Rex 
Hela cells constitutively expressing the 
tetracycline repressor protein (tetR) were co-
transfected with pGL4.31, a plasmid encoding a 
Gal4-driven luciferase reporter gene and either 
with a plasmid encoding a tetracycline-driven 
FL-NRXN3β fused to the Gal4 DNA-binding 
domain and to the VP16 activation domain 
(NRXN3β-GV), or encoding the C-terminal APP 
fragment fused to Gal4-VP16 (APP-C99-GV). In 
the absence of tetracycline, tetR binds to the 
tetracycline operator and represses the 
transcription of both NRXN3β-GV and APP-
C99-GV, resulting in low expression of 
luciferase reporter and luminescence (Fig. 4B). 
Added tetracycline results in tetR release from 
the tetracycline operator and consequently to the 
expression of the chimeric proteins NRXN3β-
GV or APP-C99-GV. As shown in Fig. 4B, we 
found a 10-20-fold increase in the luminescence 
following tetracycline treatment. This activation 
is largely dependent on γ-secretase activity that 
releases NRXN3β-ICD-GV and APP-ICD-GV 
from the membrane, and activate transcription of 
the luciferase reporter gene. Supporting a γ-
secretase-dependent activation of the luciferase 
assay, addition of 10 µM DAPT triggered a 
~75% and ~52% reduction in the luminescence 
emitted in cells expressing NRXN3β-FL-GV and 
APP-C99-GV, respectively (Fig. 4B, left). 
DAPT further leads to the accumulation of both 
NRXN3β-CTF-GV and APP-C99-GV (Fig. 4B, 
right). Taken together, these data further support 
intracellular α- and γ-secretase-dependent 
NRXN3β cleavage and suggest the release into 
the cytosol of NRXN3β-ICD.  
 
 
γ-Secretase-dependent Intramembrane 
NRXN3β-CTF processing and NRXN3β-ICD 
production. The intracellular domains (ICDs) of 
known γ-secretase substrates are rapidly 
degraded in intact cells (43). Therefore, to assay 
whether NRXN3β-CTFs can directly be 
processed by γ-secretase, thus releasing 
NRXN3β-intracellular domains (NRXN3β-
ICDs), three different cell-free assays were used. 
First, we used membrane assays, based on the 
procedure reported by Marambaud et al. (38) and 
by using membranes isolated from CHO cells 
stably expressing NRXN3β (Fig. 5A). A second 
assay was developed, using Flag-tagged 
NRXN3β-CTFs purified from HEK293T cells 
and highly purified γ-secretase (Fig. 5B). A third 
assay was developed using recombinant Flag-
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 8 
tagged NRXN3β-CTFs purified from E. coli and 
purified γ-secretase (Fig. 5C). As shown in Fig. 
5A (top panel), incubation for 3 hours at 37°C of 
membranes from CHO cells stably 
overexpressing NRXN3β resulted, in contrast to 
membranes incubated on ice, in the generation of 
a ~12kDa NRXN3β-ICD product (Fig. 5A, 
compare lane 3 with lanes 1 and 2). To test 
whether γ-secretase activity was responsible for 
the NRXN3β-ICD production, membranes were 
incubated at 37°C in the presence or absence of 
1µM of the γ-secretase inhibitors DAPT (Fig. 
5A, lane 4) or CpdE (Fig. 5A, lane 5). As 
expected, DAPT and CpdE both abolished the 
production of NRXN3β-ICD. Interestingly, we 
also observed elevated NRXN3β-CTFs levels in 
membranes incubated with DAPT or CpdE (Fig. 
5, compare lanes 4&5 with lanes 1-3). Elevated 
NRXN3β-CTFs levels were associated with 
reduced levels of full length NRXN3β (Fig. 5A, 
lanes 3-5), indicating that de novo α-secretase-
dependent CTFs are produced during the assays.  
In an alternative γ-secretase membrane assay 
(Fig. 5A, lower panel), CHO cells stably 
overexpressing NRXN3β were first incubated for 
16 hours in the presence or absence of 10 µM 
DAPT, before being used to prepare membranes. 
In contrast to membranes prepared from DAPT-
treated cells, incubation for 2 hours at 37°C of 
membranes prepared from DAPT-free cells 
resulted in the production of NRXN3β-ICD (Fig. 
5A, lanes 6&7).  
 
We next assessed whether cellular NRXN3β-
CTF can be processed by purified γ-secretase 
(Fig. 5B). HEK293T cells transiently transfected 
with FL-NRXN3β-Flag were first incubated for 
16 hours with 10µM DAPT, to trigger 
intracellular accumulation of NRXN3β-CTFs (as 
shown in Fig. 1A, lane 2). Cell lysates were 
prepared and Flag-tagged proteins (including FL-
NRXN3β-Flag and Flag-tagged NRXN3β-CTFs) 
further purified with M2 anti-Flag affinity resin. 
NRXN3β−based proteins were eluted in 0.2% 
CHAPSO-HEPES buffer for compatibility with 
our in vitro γ-secretase assay. As expected, 
western blot analysis of the purified proteins 
displayed high levels of both the full-length 
NRXN3β as well as its CTF (Fig 5B, lane 1). 
Using this partially purified substrate, in vitro γ-
secretase assays were performed as previously 
described (37,44). Basically, the reaction 
mixtures contained the cellular NRXN3β-CTF 
substrate, the purified γ-secretase solubilized in 
0.2% CHAPSO-HEPES, pH 7.5, 0.025% 
phosphatidylethanolamine (PE) and 0.10% 
phosphatidylcholine (PC). After 4 hours 
incubation at 37°C, the reactions were stopped 
by adding Laemmli buffer, and the samples were 
assayed for Flag-tagged ICDs production by 
western blot analysis. Confirming our results 
generated in the membrane assays described 
above, incubation of the purified NRXN3β with 
purified γ-secretase led to the production of a 
~12kDa NRXN3β-ICD (Fig. 5B, lane 2). This 
processing was γ-secretase-specific as DAPT and 
CpdE reduced by ~48% and ~65% NRXN3β-
ICD production, respectively (Fig. 5B, compare 
lanes 3&4 with lane 2, and densitometric 
analyses).  
To get new insight into the sequence 
requirements for NRXN3β-CTF intramembrane 
cleavage, we generated recombinant NRXN3β-
CTFs of different length. Based on size 
estimation of the major NRXN3β-CTF 
accumulating in CHO cells stably expressing 
NRXN3β (see Fig. 1B), we expressed in E.coli 
recombinant NRXN3β-CTFs (rNRXN3β-CTFs) 
of different length, that we extracted from 
inclusion bodies, purified using an M2 Flag 
resin, and used as the substrate in our in vitro γ-
secretase assays (not shown). We found that the 
recombinant NRXN3β C-terminal fragment that 
includes an N-terminal 13 amino acid long short 
ectodomain stub (starting at a.a. residue 551 
according to human FL-NRXN3β numbering), 
followed by the transmembrane domain and the 
Flag-tagged cytoplasmic tail, serves as a 
substrate for γ-secretase (Fig. 5C). Consistent 
with our membrane assays and in vitro assays 
performed with cellular NRXN3β-CTFs, 
rNRXN3β-CTF-551 was specifically processed 
by γ-secretase (Fig. 5C lane 6) as DAPT and 
CpdE reduced this processing by ~58% and 
~82%, respectively (Fig. 5C, compare lanes 7&8 
with lane 6). Finally and consistently, the 
alignment of the transmembrane regions of 
NRXN3β with known γ-secretase substrates, 
revealed a recently reported leucine residue well-
conserved in these TMDs (45) (supplementary 
figure S1). 
  
 
DISCUSSION 
 
In the present study we report that 
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NRXN3β, a cell adhesion molecule playing an 
important role in establishing and maintaining 
proper synaptic function, is a substrate for α- and 
γ-secretases. We further show that the sequential 
processing of NRXN3β by α- and  γ-secretases 
generates a large extracellular ectodomain of ~80 
kDa designated sNRXN3β and a ~12 kDa 
intracellular domain NRXN3β-ICD. Finally, we 
show that cleavage of endogenous neuronal 
neurexin by α- and γ-secretases can be 
modulated by neuronal activity stimulated by 
KCl or L-Glutamate. The biological relevance of 
(1) the processing of full-length NRXN3β (FL-
NRXN3β), (2) the generation of sNRXN3β, and 
(3) NRXN3β-ICD production needs to be 
investigated but it is conceivable that cleavage of 
NRXNs by α- and γ-secretases has functional 
implications beyond the mere clearance of 
NRXNs in the context of protein turnover 
(hypotheses depicted in Fig. 6).  
First, in vivo studies shed light on the role of 
NRXNs in both the activity and plasticity of 
synapses (10,46,47). The analysis of α-NRXNs 
triple knock-out mice (which die shortly after 
birth due to respiratory failure) revealed that 
synapses were morphologically normal, but 
characterized by dramatically reduced 
transmission (48). This supports α-NRXNs as 
proteins essential for proper synaptic function, 
but not for the initial formation of the synapse. 
The extracellular N-terminus of α-NRXNs 
contains three large repeats composed of two 
similar LNS (laminin, neurexin, sex hormone 
binding-globulin) domains responsible for the 
physical interaction across the synaptic cleft with 
the cholinesterase-like domain of neuroligins 
(NLGNs) (49). The β-NRXNs, which are 
essentially N-terminally truncated α-NRXNs, 
also display an LNS domain. The 
transmembrane domain and C-terminal 
cytoplasmic tail of α and β-NRXNs are strictly 
identical (with the very C-terminal part of all 
NRXNs cytoplasmic tails bearing a PDZ II 
binding motif that is essential for targeting 
NRXNs to the presynaptic terminals and for the 
recruitment of scaffolding proteins (47,50)). 
Hence, both α- and β-NRXNs, through physical 
interactions with NLGNs on the extracellular 
side of the membrane and scaffolding proteins 
on the cytoplasmic side, are directly implicated 
in the assembly of synapses. Therefore, we can 
speculate that processing of FL-NRXN3β by α-
secretase and γ-secretase is able to modulate the 
activity of synapses (Fig. 6). 
The production of the soluble large 
ectodomain sNRXN3β drew our attention as 
well since several studies using different 
experimental approaches and aiming to induce 
NLGNs clustering by using soluble NRXN1βs 
fragments (rat a.a. 1-299 or mouse a.a. 1 to 272), 
have demonstrated inhibitory effects on NLGNs-
associated synaptic functions, for instance 
presynaptic vesicle clustering (9,51). Moreover, 
five canonical alternative splicing sites have 
been identified in the α-isoforms of NRXNs (site 
1 to 5), two of which (4 & 5) are shared by the β-
isoforms. At these sites, splicing results in the 
insertion (or not) of sequences ranging from few 
to up to 191 amino-acid residues (1-3). 
Interestingly, and specifically for the NRXN3 
gene, the alternative splicing in the site 5 can 
result in secreted NRXN3 proteins (3). In this 
context, a genome-wide study analyzing 
mutations associated with alcohol dependence 
recently reported the occurrence of mutations in 
the NRXN3 gene, in a region that controls the 
generation of transmembrane or soluble NRXN3 
proteins (52). Finally, functional interaction of 
Neurexins ectodomain with GABAA receptors 
has been recently identified (8). Hence, it is 
likely that soluble Neurexin NTFs can modulate 
this channel activity. Taken together, these 
observations suggest a mechanism by which 
soluble NRXN3β (sNRXN3β) released into the 
synaptic cleft, resulting either from mutations in 
the NRXN genes or FL-NRXNs processing by 
α-secretases, can affect synaptic activity (Fig. 6).  
We also found that the processing by γ-
secretase of NRXN3β-CTFs releases a ~12 kDa 
intracellular domain NRXN3β-ICD. Studies on 
different γ-secretase substrates including the 
Notch receptor, APP, p75, the insulin receptor or 
the voltage-gated sodium channel B2 subunit 
have unravelled the role of γ-secretase cleavage 
and ICD release in inter- or intra-cellular 
signalling pathways and downstream 
transcriptional regulation of nuclear target genes 
(53-56). Yet, NRXN3β-ICD contains the PDZ II 
binding motif that is required for its binding to 
cytoplasmic partners, such as CASK and Mint, 
and functions as a scaffold protein for vesicle 
clustering (50,57). Moreover, the NRXNβ 
intracellular domain has recently been reported 
to interact with and participate in the proper 
targeting of nicotinic receptors (58). Whether 
NRXN3β-ICD also triggers signalling pathways 
and/or affects neurotransmitter vesicle clustering 
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and release remains unknown and needs further 
investigation.  
Moreover, we found that several mutations in 
the catalytic core of γ-secretase known to cause 
aggressive early-onset forms of Alzheimer’s 
disease (59), impair the processing of NRXN3β. 
In total agreement with our findings, PS1-L166P 
and PS1-ΔΕ9 have been reported to cause a loss 
in APP and Notch substrate processing (60). 
Because over 100 missense mutations in the PS 
genes are known to cause familial, early-onset 
AD, it remains important to investigate whether 
impaired NRXN3β processing and 
sNRXN3β/NRXN3β-ICD production can 
participate to the neuronal defects associated 
with a loss of presenilin/γ-secretase function 
(31,32). Similarly, mutations in NRXN1, which 
have been reported to cause autism spectrum 
disorders or schizophrenia (61-63), might cause 
impaired NRXN1 processing and 
sNRXN1/NRXN1-ICD production. 
In conclusion, the present data demonstrate 
that NRXN3β can be processed by α- and γ-
secretases, leading to the formation of two final 
products: a ~80 kDa N-terminal extracellular 
sNRXN3β and a ~12 kDa C-terminal 
intracellular NRXN3β-ICD, with both of them 
being potentially implicated in the regulation of 
the activity and plasticity of synapses, and signal 
transduction pathways. 
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FIGURE LEGENDS 
 
Fig. 1. NRXN3β is processed by α- and γ-secretases. Accumulation of NRXN3β-CTFs in 
HEK293T cells expressing transiently (A) or CHO cells expressing stably (B) human (h) FL-
NRXN3β-Flag, exposed for 16 hours to DMSO (0.5 % w/v final), 10 µM of γ-secretase inhibitors 
DAPT or CpdE, 20 µM TACE inhibitor TAPI-1, 5 µM BACE1 inhibitor GL189, in the presence or 
absence of 0.5 µM PMA. Whole cell lysates were immunoblotted with anti-Flag antibodies. Non-
transfected CHO cells are labelled CHO-. C. Accumulation of endogenous NRXN-CTFs in mouse (m) 
primary cortical neurons (14 DIV) treated as in (A/B). Flag-tagged hNRXN3β proteins purified from 
DAPT-treated HEK293T cells expressing transiently FL-NRXN3β-Flag were used as size controls for 
endogenous NRXN3β-FL and -CTFs. Linked arrowheads show full-length and glycosylated NRXN 
(64). The asterisks designate a minor band immunoreactive for NRXN3β. D. Sequence comparisons of 
transmembrane domains (grey) and cytosolic C-terminal domains of sixteen canonical Neurexin 
isoforms. Identical residues in all sequences are marked by an asterisk; conserved substitutions are 
marked by a colon. E. Neuronal activity dependent accumulation of murine NRXN-CTFs. Following 
stimulation of PCN with either 50µM L-Glutamate or 50mM KCl, microsomal membrane preparations 
were incubated with DAPT (1 µM) or DMSO at 37°C for 4 hours, and protein extracts immunoblotted 
with antibodies to the C-terminus of NRXNs. Densitometric analysis revealed a significant increase in 
CTFs when neurons were treated with L-Glutamate or KCl as compared to non-treated ones. Results 
are expressed as mean +/- SD of triplicate luminescence measurements (n=3, *p < 0.05, t-test). 
 
Fig. 2. α-Secretase-mediated release of extracellular sNRXN3β. HEK293T cells transiently 
expressing Flag-tagged full-length NRXN3β were maintained overnight in DMEM 10% FBS, washed 
and conditioned for 16 hours in serum-free DMEM medium containing 0.5 µM of PMA or 20 µM of 
TAPI-1, respectively an activator and inhibitor of α-secretases of the ADAM family. The conditioned 
media were concentrated by TCA precipitation and probed by western blotting with an anti NRXN3β 
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antibody specific for the N-terminal ectodomain (A), or an M2 anti-Flag antibody targeting the C-
terminus of full length NRXN3β (B). A total cell lysate from HEK293T cells transiently expressing 
FL-NRXN3β-Flag (hNRXN3β control; lane1) and conditioned medium from untransfected HEK293T 
cells (-) were loaded as controls. 
 
 
Fig. 3. Partial loss of γ-secretase activity impairs NRXN3β processing. A. Alzheimer’s disease 
causing mutants of PS1 impair NRXN3β processing. NRXN3β-CTFs were analyzed in CHO cells 
stably expressing FL-NRXN3β and transiently expressing increasing amounts of WT PS1 (lanes 
2&3), or the Alzheimer’s disease causing mutants PS1-L166P, PS1-P436Q and PS1-ΔE9 (lanes 4-9). 
FL-NRXN3β, NRXN3β-CTFs, PS1-NTF, FL-APP and APP-CTFs were probed by Western blotting 
using the M2 anti-Flag (for FL-NRXN3β/NRXN3β-CTFs), anti-hPS1, and anti-amyloid precursor 
protein (for FL-APP/APP-CTFs) C-terminal antibody (upper panel). Lower panel: the levels of 
hNRXN3β- and APP-CTFs were quantified by densitometric analysis of the bands in the Western 
blot. For accurate quantification, the relative levels of CTFs were normalized to these of full-length 
NRXN3β and APP (CTFs:FL). LV indicates the volume of lentivirus preparation used to infect 2*106 
CHO cells. β-actin serves as a loading control. B. Impaired NRXN3β processing in PS1/PS2 double 
knock-out MEFs. Representative western-blot analysis of NRXN3β-CTFs in wild-type mouse 
embryonic fibroblasts (MEF WT, lane 1), in PS1/PS2 double knock-out MEFs (MEF DKO, lane 2) 
and in PS1/PS2 double knock-out MEFs expressing hPS1 WT (MEF DKO + PS1, lane 3). *: minor 
band immunoreactive for NRXN3β.  
 
 
Fig. 4. γ-Secretase-dependent processing of NRXN3β in a cell-based luciferase reporter assay A. 
Schematic representation of the NRXN3β-specific luciferase reporter assay. Full-length NRXN3β 
fused to the Gal4 DNA-binding domain and to the VP16 activation domain (NRXN3β-FL-GV) was 
expressed under the control of the tetracycline operator (TO) in T-Rex Hela cells constitutively 
expressing the tetracycline repressor (tetR) protein transfected with pGL4.31, a plasmid encoding a 
Gal4-driven luciferase reporter gene. In the absence of tetracycline (-Tet), tetR binds to the 
tetracycline operator and represses the transcription of NRXN3β-FL-GV, resulting in low expression 
of luciferase reporter. Added tetracycline (+ Tet) results in tetR release from the tetracycline operator 
and consequently to the expression of the chimeric proteins NRXN3β-FL-GV, and high expression of 
luciferase reporter. In this system, sequential processing by α- and γ-secretase of NRXN3β-FL-GV 
leads to the formation of NRXN3β-ICD-GV which gets released from the membrane and translocated 
into the nucleus where it activates transcription of the luciferase reporter gene. Inhibition of α- or γ-
secretase is thus expected to prevent expression of the luciferase reporter gene. B. The γ-secretase 
inhibitor DAPT blocks the proteolysis of NRXN3β-CTF-GV or APP-C99-GV and prevents the 
expression of the luciferase reporter gene. Left: luminescence (counts per second) emitted by cells 
treated with tetracycline (1µg/ml), in the presence or absence of DAPT (10 µM). Results are expressed 
as means +/- SD of triplicate luminescence measurements (n=3, *p < 0.05, t-test). Right: a 
representative reaction was western blotted for NRXN3β-GV and APP-C99-GV by using an anti 
VP16 antibody. Light (top) and dark (bottom) exposures are shown.  
 
 
 
   Fig. 5. γ-Secretase-dependent processing of NRXN3β-CTFs and NRXN3β-ICD production. A. γ-
Secretase activity assays performed with membranes isolated from CHO cells stably expressing full 
length NRXN3β-Flag. Cell membranes enriched in FL-NRXN3β-Flag were incubated for 3 hours at 
37°C in the presence or absence of 1µM DAPT or 1 µM Compound E (CpdE) (lanes 1-5). 
Alternatively, membranes prepared from cells incubated for 16 hours in the presence or absence of 
DAPT (10 µM) were incubated for 2 hours at 37°C (lanes 6&7). B. γ-Secretase activity assays 
performed with purified NRXN3β-based substrates and purified γ-secretase. Flag-tagged NRXN3β-
CTFs purified from HEK293T cells transiently expressing FL-NRXN3β-Flag were incubated with 
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purified γ-secretase, for 4 hours at 37°C, with 0.1% PC, 0.025% PE, and in the presence or absence of 
1 µM DAPT or CpdE. NRXN3β-ICDs in the representative western blot were quantified by 
densitometry (right panel) and normalized to the NRXN3β-ICDs produced in the absence of γ-
secretase inhibitor (100%) C. γ-Secretase activity assays performed with purified recombinant 
NRXN3β-based substrates and purified γ-secretase. Left panel: schematic representation of the 
membrane anchored full-length NRXN3β and the recombinant NRXN3β-CTF substrate consisting of 
the C-terminal amino acids 551-630 plus a methionine residue at the N-terminus and a Flag tag at the 
C-terminus. The grey box (amino-acid residues 564-584) represents the predicted transmembrane 
domain. Middle panel: γ-secretase from solubilized S20 membranes diluted in 0.25% CHAPSO-
HEPES, pH 7.5, was incubated at 37°C for 4 hours with 1 µM APP-C100Flag (lanes 1-4) or 1 µM 
rNRXN3β-CTF-551  (lanes 5-8), 0.1% PC, 0.025% PE, in the presence or absence of 1 µM DAPT or 
CpdE. The reactions were western blotted for AICD-Flag and NRXN3β-ICD-Flag by using the anti 
Flag M2 antibody. Recombinant NRXN3β-ICDs and AICDs in the representative Western blots were 
quantified by densitometry (right panel) and normalized to the ICDs produced in the absence of γ-
secretase inhibitor (100%).  
 
 
Fig. 6. Model for NRXN3β processing by α- and γ-secretases, and hypothetical implications on 
synaptic activity and plasticity. Full-length NRXN3β (FL-NRXN3β) is synthesized as a type I 
transmembrane protein forming trans-synaptic complexes with Neuroligins (NLGNs) required for 
synapse maturation and function (A). FL-NRXN3β can undergo cleavage at the α-secretase sites to 
release large ectodomains designated sNRXN3β, and leave membrane-embedded fragments 
NRXN3β-CTFs (B). Proteolysis of these CTFs by γ-secretase releases intracellular domains NRXN3β-
ICDs, and extracellular NRXN3β peptides (NRXN3β-Ps). Considering the essential roles of NRXNs 
in synaptic activity and plasticity, one can speculate that the processing of FL-NRXN3β by α-
secretase (1), and/or the release of soluble sNRXN3β into the synaptic cleft (2) can modulate NLGNs 
and NRXN-dependent activities. The intracellular release of NRXN3β-ICD (3) might trigger 
signalling pathways and/or affect neurotransmitter vesicle clustering and release.  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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